169 related articles for article (PubMed ID: 21169731)
21. [Evaluation of the medical treatment of Graves' disease (GD)].
Peixoto MC; Coeli CM; Vaisman M
Arq Bras Endocrinol Metabol; 2005 Jun; 49(3):410-9. PubMed ID: 16543996
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of perinuclear antineutrophil cytoplasmic antibody in patients with Graves' disease treated with propylthiouracil or methimazole in Taiwan.
Huang CN; Hsu TC; Chou HH; Tsay GJ
J Formos Med Assoc; 2004 Apr; 103(4):274-9. PubMed ID: 15175822
[TBL] [Abstract][Full Text] [Related]
23. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
[TBL] [Abstract][Full Text] [Related]
24. Serum BAFF concentrations in patients with Graves' disease and orbitopathy before and after immunosuppressive therapy.
Vannucchi G; Covelli D; Currò N; Dazzi D; Maffini A; Campi I; Bonara P; Guastella C; Pignataro L; Ratiglia R; Beck-Peccoz P; Salvi M
J Clin Endocrinol Metab; 2012 May; 97(5):E755-9. PubMed ID: 22399512
[TBL] [Abstract][Full Text] [Related]
25. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
26. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
[TBL] [Abstract][Full Text] [Related]
27. Circulating immune complexes and thyroid-stimulating immunoglobulins before, during, and after antithyroid drug therapy in patients with Graves' disease.
van der Heide D; Daha MR; Bolk JH; Bussemaker JK; de Bruin TW; Goslings BM; van Es LA; Querido A
Lancet; 1980 Jun; 1(8183):1376-9. PubMed ID: 6155582
[TBL] [Abstract][Full Text] [Related]
28. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
29. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
30. Elevated serum granulocyte colony-stimulating factor levels in patients with Graves' disease.
Iitaka M; Noh JY; Kitahama S; Fukasawa N; Miura S; Kawakami Y; Kawasaki S; Yamanaka K; Ishii J; Katayama S; Ito K
Clin Endocrinol (Oxf); 1998 Mar; 48(3):275-80. PubMed ID: 9578815
[TBL] [Abstract][Full Text] [Related]
31. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
[TBL] [Abstract][Full Text] [Related]
32. A 6-year follow-up of a randomized prospective trial comparing methimazole treatment with or without exogenous L-thyroxine in Chinese patients with Graves' disease.
Liu X; Qiang W; Liu X; Liu L; Liu S; Gao A; Gao S; Shi B
Exp Clin Endocrinol Diabetes; 2014 Nov; 122(10):564-7. PubMed ID: 25140995
[TBL] [Abstract][Full Text] [Related]
33. Relationship between longitudinal behaviour of some markers of eye autoimmunity and changes in ocular findings in patients with Graves' ophthalmopathy receiving corticosteroid therapy.
De Bellis A; Bizzarro A; Conte M; Coronella C; Solimeno S; Perrino S; Sansone D; Guaglione M; Wall JR; Bellastella A
Clin Endocrinol (Oxf); 2003 Sep; 59(3):388-95. PubMed ID: 12919164
[TBL] [Abstract][Full Text] [Related]
34. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy.
Bartalena L; Marcocci C; Bogazzi F; Manetti L; Tanda ML; Dell'Unto E; Bruno-Bossio G; Nardi M; Bartolomei MP; Lepri A; Rossi G; Martino E; Pinchera A
N Engl J Med; 1998 Jan; 338(2):73-8. PubMed ID: 9420337
[TBL] [Abstract][Full Text] [Related]
35. Effect of methimazole treatment for 2 years on circulating IL-4, IgE, TBII, and TSAb in patients with hyperthyroid Graves' disease.
Yamada T; Komiya I; Miyahara Y; Komatsu M; Shima I; Inazawa T; Aizawa T
Endocr J; 2006 Dec; 53(6):783-8. PubMed ID: 16983180
[TBL] [Abstract][Full Text] [Related]
36. Frequency of antineutrophil cytoplasmic antibody in Graves' disease patients treated with methimazole.
Gumà M; Salinas I; Reverter JL; Roca J; Valls-Roc M; Juan M; Olivé A
J Clin Endocrinol Metab; 2003 May; 88(5):2141-6. PubMed ID: 12727967
[TBL] [Abstract][Full Text] [Related]
37. [Effects of methimazole on the evolution of the allergic rhinitis of patients with Graves' disease].
Valencia Zavala MP; Cortinas López L; Sánchez Olivas JA; Sánchez Olivas MA; Montes Montes J; Duarte Díaz RJ; León Oviedo C
Rev Alerg Mex; 2007; 54(3):71-6. PubMed ID: 17849791
[TBL] [Abstract][Full Text] [Related]
38. Analysis of Ig/Ig two-component-determined circulating immune complexes (TCIC) provide new insights into host immunity.
Wang S; Yang T; Zhang J; Xiao S; Peng X
Int Immunopharmacol; 2003 Oct; 3(10-11):1549-55. PubMed ID: 12946452
[TBL] [Abstract][Full Text] [Related]
39. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking.
Salvi M; Pedrazzoni M; Girasole G; Giuliani N; Minelli R; Wall JR; Roti E
Eur J Endocrinol; 2000 Aug; 143(2):197-202. PubMed ID: 10913938
[TBL] [Abstract][Full Text] [Related]
40. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis.
Conti F; Ceccarelli F; Perricone C; Alessandri C; Conti V; Massaro L; Truglia S; Spinelli FR; Spadaro A; Valesini G
Rheumatology (Oxford); 2011 Jun; 50(6):1148-52. PubMed ID: 21278072
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
